Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Health In Tech, Inc. is asking stockholders at its virtual November 10, 2026 annual meeting to elect five directors and vote on four other proposals: increase authorized capital stock from 220,000,000 to 720,000,000 shares; approve SEPA share issuance exceeding 20% of issued and outstanding Class A Common Stock; increase the 2024 Plan’s Class A share authorization from 10,677,849 to 20,677,849; and ratify MaloneBailey, LLP as auditor for 2026.
The SEPA gives Health In Tech the right to sell Yorkville up to $20.0 million of Class A Common Stock, subject to conditions. Sales and timing are at the company’s option, and it is under no obligation to sell. If approved, the share authorization proposal would add 500,000,000 authorized Class A shares; the company says future issuance could dilute voting rights, earnings per share and book value per share. Health In Tech also disclosed it is not meeting Nasdaq’s board-independence and Audit Committee requirements following director Sanjay Shrestha’s August 10, 2026 resignation. It intends to regain compliance by appointing an independent director before the February 6, 2027 cure-period deadline.
Health In Tech, Inc. (HIT) registered for resale by Yorkville up to 34,224,247 shares of Class A common stock, comprising up to 9,532,889 conversion shares and up to 24,691,358 advance shares. HIT receives no proceeds from Yorkville’s resales, but may receive up to $14.25 million in aggregate gross proceeds from Convertible Note sales and up to $20.0 million from stock sales to Yorkville under the SEPA. The first $6.65 million net advance was disbursed August 18, 2026, in exchange for a $7 million principal note, initially convertible at $1.5735 per share, subject to adjustment. Advance Shares are priced at 97% of the lowest daily VWAP during a three-trading-day pricing period, subject to stated exclusions.
Issuances are limited to 13,100,378 shares (19.99%) unless stockholders approve more; HIT will seek approval at its annual meeting on or about November 10, 2026. A separate 4.99% beneficial ownership limit applies. HIT estimates that, if all registered shares were issued and outstanding, they would represent approximately 39.0% of total outstanding common shares as of October 6, 2026, and states that issuance would dilute existing holders’ economic and voting interests.
Health In Tech, Inc. (HIT) director Timothy Hayes acquired 26,301 shares of Class A Common Stock on October 7, 2026, as restricted shares granted under the Health In Tech Equity Incentive Plan. The shares vested as of their grant date, and the reported transaction price was $0.76 per share. Hayes reported direct holdings of 135,081 shares afterward.
Health In Tech, Inc. director William D. Howard acquired 26,301 shares of restricted Class A Common Stock on October 7, 2026, under the Health In Tech Equity Incentive Plan. The shares vested on their grant date. The reported price was $0.76 per share, and Howard’s direct holdings following the grant were 164,811 shares.
Health In Tech, Inc. is asking stockholders to vote at its virtual November 5, 2026 annual meeting on five director nominees and four other proposals: raise authorized capital stock from 220,000,000 to 720,000,000 shares; approve SEPA-related Class A issuance exceeding 20% of issued and outstanding Class A shares; increase the 2024 Plan’s Class A authorization from 10,677,849 to 20,677,849 shares; and ratify MaloneBailey, LLP as auditor for 2026.
The share proposal allocates 650,000,000 Class A, 50,000,000 Class B and 20,000,000 preferred shares, including 500,000,000 additional authorized Class A shares. The company says future issuance could dilute voting rights, earnings per share and book value per share. Under its agreement with Yorkville, Health In Tech may sell up to $20.0 million of Class A shares, subject to limitations and conditions; described possible issuances include up to 9,532,889 conversion shares and up to 20,000,000 Advance Shares. The company also disclosed Nasdaq noncompliance with board-independence and audit-committee requirements after Sanjay Shrestha’s August 10, 2026 resignation, and intends to regain compliance by appointing an independent director before the February 6, 2027 cure deadline.
Health In Tech, Inc. (HIT) launched HitRix, an AI-powered platform designed to simplify large-group self-funded health insurance workflows. Brokers can upload case information in the formats they receive; HitRix uses document intelligence to ingest, extract, organize and structure it, then supports submissions across carriers and managing general underwriters, tracks market activity and compares proposals in one environment. The platform is integrated with Health In Tech’s underwriting and marketplace infrastructure.
Health In Tech updated its full-year 2026 revenue outlook to approximately $33 million, roughly in line with 2025 revenue. The company said the outlook primarily reflects the timing of HitRix commercialization, its Three-Year Rate Stabilization Program and additional carrier capacity, which affect the timing of new policy effective dates and related revenue recognition. It expects these initiatives to contribute more meaningfully beginning in 2027 and beyond.
HitRix launched across the company’s existing distribution ecosystem of brokers, third-party administrators and agencies.
Health In Tech, Inc. (HIT) is the issuer in a Schedule 13G reporting that Laurence W. Lytton, identified as the reporting person, beneficially owned 3,317,030 shares of Class A common stock, equal to 6.2% of the class. He reported shared voting and dispositive power over 3,317,030 shares, and sole voting and dispositive power of zero shares. The percentage was calculated using 53,834,658 Class A shares outstanding as of August 12, 2026.
Health In Tech, Inc. (HIT) reported that Chief Growth Officer Hasan Zain Syed disposed of 4,795 shares of Class A Common Stock on September 15, 2026 through a tax-withholding transaction related to vesting of restricted stock. The shares were surrendered to the company to satisfy tax obligations. Following this transaction, Syed directly holds 183,749 Class A shares, including 168,538 restricted shares and 15,211 unrestricted shares. No Rule 10b5-1 trading plan is reported for this transaction.
Health In Tech, Inc. (HIT) reported that Chief Executive Officer and director Qian LinLin had 33,725 shares of Class A Common Stock withheld on September 15, 2026 to satisfy tax withholding and remittance obligations upon vesting of previously granted restricted stock. After this tax-withholding disposition, LinLin directly holds 8,964,667 Class A shares, including 887,062 restricted and 8,077,605 unrestricted shares, and continues to hold 2,700,000 Class B shares and 711,510 options to purchase Class A shares, which are excluded from that direct Class A share total.
Health In Tech, Inc. (HIT) reported that Chief Executive Officer and director Tim Donald Johnson surrendered 63,339 restricted shares of Class A Common Stock to the company on September 15, 2026 to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock. After this tax-withholding disposition, he holds 23,271,026 Class A shares, consisting of restricted and unrestricted stock, in addition to separate holdings of Class B shares and stock options.